Why Most Technology Assessments Miss the Real Risk
- Arise Innovations
- 28. Juni
- 4 Min. Lesezeit
A technology evaluation lands on a decision-maker’s desk. Forty pages. Detailed. The tech works. The science is sound. The recommendation: proceed.
Eighteen months later, the investment has stalled. Not because the technology failed — but because the assessment never asked the questions that would have revealed the real risk: a manufacturing process that does not scale, a regulatory pathway that took three years longer than assumed, a competitive landscape that shifted in a dynamic market while the assessment was being written.
This is not a rare occurrence. It is the default outcome of technology assessments that evaluate the wrong dimensions. The technology works — but the investment thesis does not.
The Problem
Technology assessments are commissioned when someone needs to make a decision under uncertainty. An M&A committee evaluating a €12M acquisition. A corporate R&D team deciding whether to license a new process. A government programme allocating €50M across competing proposals. A startup founder preparing evidence for a Series A. In each case, the question is structurally identical: is this technology worth the commitment we are about to make?
The standard approach evaluates technical performance. Does the technology do what it claims? What is the readiness level? What are the remaining technical risks? These questions are necessary but insufficient. They evaluate the technology in isolation — disconnected from the commercial, regulatory, manufacturing, and competitive context that determines whether the investment will succeed.
The result: assessments that are technically correct and commercially irrelevant.
Consider three scenarios. A venture capital firm commissions a technology assessment for a portfolio candidate. The report confirms TRL 6, — “technology demonstrated in a relevant environment.” What the assessment does not evaluate: the relevant environment was a university laboratory, and the path from laboratory to production requires additional €8M in capital equipment and 24 months of process development. The VC invests based on the TRL number. The venture runs out of capital before reaching production scale.
A corporate innovation team evaluates whether to adopt a new manufacturing process. The assessment confirms superior performance — 30% faster, 20% cheaper in direct costs. What the assessment does not evaluate: the new process requires retraining the entire production workforce, replacing quality control infrastructure, and re-qualifying with every downstream customer. The total switching cost exceeds the performance benefit by a factor of three.
A founder hires a consultant to produce a technology assessment for fundraising. The assessment is optimistic — because the consultant’s incentive is to produce an assessment the founder can use, not an assessment that might reveal uncomfortable truths. The investor who reads the assessment cannot distinguish between independent evaluation and commissioned advocacy.
In each case, the assessment answered the question “does the technology work?” instead of answering the question “should we commit resources to this technology?”
Why Standard Technology Assessment Approaches Fail
Approach 1: Single-dimension evaluation. Most technology assessments are conducted by specialists — engineers who evaluate technical performance, or business analysts who evaluate market size. Neither perspective alone captures the multi-dimensional reality of technology risk. A technology can perform brilliantly and be commercially unviable. A technology can address a massive market and be physically impossible to manufacture at target cost (McKinsey, 2023).
Approach 2: Expert calls as due diligence. Expert calls offer opinion, not analysis. An expert can tell you what they think. They cannot produce a structured risk assessment with documented evidence, quantified uncertainties, and traceable assumptions. When millions are at stake, opinion is not due diligence.
Approach 3: Commissioned assessments without independence. When the entity commissioning the assessment has a stake in the outcome — a founder wanting a positive report, a corporate team wanting validation for a project they champion — the assessment loses its diagnostic value. Independence is not a preference. It is a
structural requirement for assessment credibility (Lerner & Nanda, 2020).
The Consequences
Flawed technology assessments do not produce spectacular failures. They produce slow, invisible capital erosion. The investment proceeds. The technology works — partially. Progress is visible but insufficient. By the time the real risk becomes undeniable, the sunk cost has created institutional inertia that prevents course correction.
The average cost of a failed technology investment in mid-market PE is $15-45M. The average cost of a comprehensive, independent technology assessment: $15,000-25,000. The asymmetry is staggering — and yet most organisations spend more on legal due diligence than on evaluating whether the technology itself will deliver what they are paying for (CB Insights, 2024).
For founders, the consequence is different but equally damaging: a weak assessment burns investor credibility. An investor who reads a technology assessment and later discovers it was incomplete will not re-engage. The first impression is the only impression.
Continue reading: the full article — including a 5-points decision framework and 10-points self-assessment — is available here.
Organizations rarely struggle with a lack of information. They struggle with too much of it, scattered.
Market signals, technical evidence, competitor activity, customer feedback, regulatory developments, financial data and internal assumptions often point in different directions.
Second-order effects are being left out of the equation.
Yet strategic decisions still need to be made.
I help organizations reduce uncertainty by turning complex, fragmented and multi-domain information into independent, evidence-based decision assets.
Kommentare